Clinical trials: sponsored by Beijing InnoCare Pharma Tech Co., Ltd.
Inflammatory Bowel Disease(IBD)
Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers
This is a randomized, double-blind, placebo-controlled, ascending dose study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part (Part B).
- Trial name
- NCT07911982
- Testing
- ICP-B161 (SC or IV)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Health Services Research
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
- Trial name
- NCT07535099
- Testing
- ICP-538 Tablets
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Hepatic Impairment
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
This is an Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects with Varying Degrees of Hepatic Impairment
- Trial name
- NCT05684653
- Testing
- Orelabrutinib Tablets
- Where
- 4 sites in China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Psoriasis
A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects…
- Trial name
- NCT05451199
- Testing
- ICP-488
- Where
- 7 sites in China
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Healthy Subject
Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
This is A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
- Trial name
- NCT05660720
- Testing
- Orelabrutinib, Moxifloxacin hydrochloride
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Healthy Subjects
A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, parallel group, single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-332 in Healthy Subjects
- Trial name
- NCT05399030
- Testing
- ICP-332
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Healthy Person
DDI Study of Orelabrutinib
This is a phase I, single-center, open-label, fixed-sequence clinical study. The primary objective was to evaluate the effects of multiple administrations of rifampin or itraconazole on the pharmacokinetic characteristics of a…
- Trial name
- NCT05316857
- Testing
- Orelabrutinib + Rifampin, Orelabrutinib + Itraconazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Healthy Volunteers
ADME Study of [14C]ICP-022 in Healthy Males
The purpose of this study is to investigate the absorption, the metabolic pathways and the excretion of ICP-022 in healthy male adult participants after administration of a single oral dose of 150 mg of 14C ICP-022.
- Trial name
- NCT04441450
- Testing
- [14C]ICP-022
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.